Modified antigen binding molecules with altered cell signaling activity

Details for Australian Patent Application No. 2012216702 (hide)

Owner Roche GlycArt AG

Inventors Umana, Pablo; Mossner, Ekkehard

Agent Davies Collison Cave

Pub. Number AU-A-2012216702

Parent 2006290433

Filing date 6 September 2012

Wipo publication date 27 September 2012

International Classifications

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 Antineoplastic agents

C12N 5/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 Mutation or genetic engineering - Immunoglobulins

Event Publications

20 September 2012 Complete Application Filed

27 September 2012 Application Open to Public Inspection

  Published as AU-A-2012216702

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012216703-Markers for detection of gastric cancer

2012216701-Redemption of virtual tickets using a portable electronic device